Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study.

Objective: To evaluate the efficacy and safety of 3 months of vaginal mifepristone treatment on leiomyoma volume and related symptoms.

Design: Prospective, open-label, two tertiary centers, phase II clinical trial.

Setting: Two tertiary medical centers in Israel.